ScholarIQanswers from OpenAlex
Royal Hospital for Women
InstitutionResearch output, impact & collaborations
Royal Hospital for Women is a institution indexed in ScholarIQ from OpenAlex.
What is known about Royal Hospital for Women?
ScholarIQrecord summary
Royal Hospital for Women is a research organisation in Sydney, AU. OpenAlex records 2,753 works and 151,998 citations for it. 538 researchers list it as their most recent affiliation.
How many works does Royal Hospital for Women have?
ScholarIQindexed works
Royal Hospital for Women has 2,753 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Royal Hospital for Women have?
ScholarIQcitation count
Royal Hospital for Women has 151,998 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Royal Hospital for Women?
ScholarIQresearcher count
Royal Hospital for Women has 538 researchers in the ScholarIQ index.
What is the average h-index at Royal Hospital for Women?
ScholarIQavg h-index
Royal Hospital for Women has an average h-index of 55.6 in OpenAlex.
What is the ROR of Royal Hospital for Women?
ScholarIQror
The ROR for Royal Hospital for Women is on the source record.
What is the OpenAlex record for Royal Hospital for Women?
ScholarIQopenalex
The OpenAlex for Royal Hospital for Women is on the source record.
Who are the most-cited researchers behind Royal Hospital for Women?
ScholarIQtop researchers by citations
What are the most-cited papers on Royal Hospital for Women?
ScholarIQmost cited works
Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers
Karoline Kuchenbaecker, John L. Hopper, Daniel R. Barnes, Kelly‐Anne Phillips, Thea M. Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E. van Leeuwen, Roger L. Milne, Nadine Andrieu, David E. Goldgar, Mary Beth Terry, Matti A. Rookus, Douglas F. Easton, Antonis C. Antoniou, Lesley McGuffog, D. Gareth Evans, Daniel Barrowdale, Debra Frost, Julian Adlard, Kai-Ren Ong, Louise Izatt, Marc Tischkowitz, Rosalind A. Eeles, Rosemarie Davidson, Shirley Hodgson, Steve Ellis, Catherine Noguès, Christine Lasset, Dominique Stoppa‐Lyonnet, Jean‐Pierre Fricker, Laurence Faivre, Pascaline Berthet, Maartje J. Hooning, Lizet E. van der Kolk, Carolien M. Kets, Muriel A. Adank, Esther M. John, Wendy K. Chung, Irene L. Andrulis, Melissa C. Southey, Mary B. Daly, Saundra S. Buys, Ana Osório, Christoph Engel, Karin Kast, Rita K. Schmutzler, Trinidad Caldés, Anna Jakubowska, Jacques Simard, Michael Friedländer, Sue‐Anne McLachlan, Eva Macháčková, Lenka Foretová, Yen Y. Tan, Christian F. Singer, Edith Oláh, Anne‐Marie Gerdes, Brita Arver, Håkan Olsson
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Paul DiSilvestro
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh, James Carmichael, Richard T. Penson, Michael Friedländer, Bethan Powell, Katherine M. Bell‐McGuinn, Clare L. Scott, Jeffrey N. Weitzel, Ana Oaknin, Niklas Loman, Karen H. Lu, Rita K. Schmutzler, Ursula A. Matulonis, Mark Wickens, Andrew Tutt
Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.
David W. Hedley, Michael Friedländer, Ian W. Taylor, Catherine A. Rugg, Elizabeth A. Musgrove
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, Michael Friedländer, Ignace Vergote, Gordon Rustin, Clare L. Scott, Werner Meier, Ronnie Shapira‐Frommer, Tamar Safra, Daniela Matei, Euan Macpherson, Claire Watkins, James Carmichael, Ursula A. Matulonis
How much of the research on Royal Hospital for Women is open access?
ScholarIQopen access share
50%OPEN ACCESS